| Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial AH Wei, P Montesinos, V Ivanov, CD DiNardo, J Novak, K Laribi, I Kim, ... Blood, The Journal of the American Society of Hematology 135 (24), 2137-2145, 2020 | 684 | 2020 |
| Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial S Saussele, J Richter, J Guilhot, FX Gruber, H Hjorth-Hansen, A Almeida, ... The Lancet Oncology 19 (6), 747-757, 2018 | 593 | 2018 |
| Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic … A Chanan-Khan, P Cramer, F Demirkan, G Fraser, RS Silva, S Grosicki, ... The Lancet Oncology 17 (2), 200-211, 2016 | 528 | 2016 |
| Interleukin‐2 receptor common γ‐chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: Selective induction of anti‐apoptotic … AN Akbar, NJ Borthwick, RG Wickremasinghe, P Panayiotidis, D Pilling, ... European journal of immunology 26 (2), 294-299, 1996 | 444 | 1996 |
| Thalidomide and dexamethasone combination for refractory multiple myeloma MA Dimopoulos, K Zervas, G Kouvatseas, E Galani, V Grigoraki, ... Annals of Oncology 12 (7), 991-995, 2001 | 431 | 2001 |
| Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label … P Hillmen, T Robak, A Janssens, KG Babu, J Kloczko, S Grosicki, ... The Lancet 385 (9980), 1873-1883, 2015 | 429 | 2015 |
| Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma M Dreyling, A Santoro, L Mollica, S Leppä, GA Follows, G Lenz, WS Kim, ... Journal of Clinical Oncology 35 (35), 3898-3905, 2017 | 415 | 2017 |
| Waldenstrom’s macroglobulinemia: clinical features, complications, and management MA Dimopoulos, P Panayiotidis, LA Moulopoulos, P Sfikakis, M Dalakas Journal of Clinical Oncology 18 (1), 214-214, 2000 | 405 | 2000 |
| Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro P Panayiotidis, D Jones, K Ganeshaguru, L Foroni, AV Hoffbrand British journal of haematology 92 (1), 97-103, 1996 | 400 | 1996 |
| Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact P Baliakas, S Jeromin, M Iskas, A Puiggros, K Plevova, F Nguyen-Khac, ... Blood, The Journal of the American Society of Hematology 133 (11), 1205-1216, 2019 | 256 | 2019 |
| Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma MC Kyrtsonis, TP Vassilakopoulos, N Kafasi, S Sachanas, T Tzenou, ... British journal of haematology 137 (3), 240-243, 2007 | 207 | 2007 |
| Interleukin‐4 inhibits apoptotic cell death and loss of the bcl‐2 protein in B‐chronic lymphocytic leukaemia cells in vitro P Panayiotidis, K Ganeshaguru, SAB Jabbar, AV Hoffbrand British journal of haematology 85 (3), 439-445, 1993 | 187 | 1993 |
| B-cell kinase lyn deficiency in patients with systemic lupus erythematosus SNC Liossis, EE Solomou, MA Dimopoulos, P Panayiotidis, ... Journal of Investigative Medicine 49 (2), 157-165, 2001 | 180 | 2001 |
| Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations V Ljungström, D Cortese, E Young, T Pandzic, L Mansouri, K Plevova, ... Blood, The Journal of the American Society of Hematology 127 (8), 1007-1016, 2016 | 167 | 2016 |
| Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study K Zervas, MA Dimopoulos, E Hatzicharissi, A Anagnostopoulos, ... Annals of Oncology 15 (1), 134-138, 2004 | 163 | 2004 |
| Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study P Baliakas, A Hadzidimitriou, LA Sutton, E Minga, A Agathangelidis, ... The lancet haematology 1 (2), e74-e84, 2014 | 158 | 2014 |
| Iron chelators induce apoptosis in proliferating cells D Hileti, P Panayiotidis, AV Hoffbrand British Journal of Haematology 89 (1), 181-187, 1995 | 151 | 1995 |
| Treatment of Waldenstrom’s macroglobulinemia with thalidomide MA Dimopoulos, A Zomas, NA Viniou, V Grigoraki, E Galani, C Matsouka, ... Journal of clinical oncology 19 (16), 3596-3601, 2001 | 147 | 2001 |
| Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care TP Vassilakopoulos, GA Pangalis, A Katsigiannis, SG Papageorgiou, ... The oncologist 17 (2), 239-249, 2012 | 145 | 2012 |
| Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma G Fraser, P Cramer, F Demirkan, RS Silva, S Grosicki, A Pristupa, ... Leukemia 33 (4), 969-980, 2019 | 139 | 2019 |
